SPORE in Genitourinary Cancer

泌尿生殖系统癌症中的孢子

• 批准号: 8917105
• 负责人: COLIN P.N. DINNEY
• 金额: $ 193.04万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-25 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8917105
• 关键词: Achievement; Address; Awareness; Bioinformatics; Biological Markers; Biology; Biometry; Calmette-Guerin Bacillus; Cancer Research Project; Cells; Chemoprevention; Clinic; Clinical; Clinical Research; Clinical Trials; Collaborations; Communities; Detection; Development; Disease; Early Diagnosis; Epidemiologist; Epigenetic Process; Equilibrium; Event; FGFR3 gene; Foundations; Funding; Gene Amplification; Genetic; Goals; Guanosine Triphosphate Phosphohydrolases; Health; Human; Incidence; Individual; Informatics; Laboratories; Laboratory Research; Leadership; Malignant neoplasm of urinary bladder; Mediating; Medical Oncologist; Molecular; Molecular Genetics; Molecular Profiling; Morbidity - disease rate; Mutation; Nature; Neoplasm Metastasis; Neoplasms; Outcome; Pathogenesis; Pathologist; Pathology; Patients; Peer Review Grants; Prevention; Prevention strategy; Publications; Recurrence; Refractory; Refractory Disease; Research Personnel; Resources; Risk; Risk Assessment; Scientist; Staging; Supportive care; Therapeutic; Translational Research; Translations; University of Texas M D Anderson Cancer Center; Urogenital Cancer; Urologist; Ursidae Family; adenoviral-mediated; advanced disease; anticancer research; base; bladder Carcinoma; career development; clinical application; data management; experience; gene therapy; genetic risk factor; high risk; improved; innovation; minimally invasive; molecular marker; mortality; multidisciplinary; new technology; novel; novel therapeutic intervention; novel therapeutics; personalized medicine; pre-clinical; programs; response; therapeutic target; tumor; tumor progression

DESCRIPTION (provided by applicant): The overall goal of this University of Texas MD Anderson Cancer Center SPORE in Genitourinary Cancer is to facilitate innovative translational research in the prevention, detection, and treatment of this disease leading to the elimination of bladder cancer (BC) as a major health problem. We have invested in several major translational research themes which include: the development of non- or minimally-invasive markers for early detection of BC in high-risk individuals or for surveillance and the early detection of recurrence in those with the disease, the identification of inherited factors that contribute to increased or decreased risk of developing BC, the elucidation of the molecular events (genetic and epigenetic) that mediate the earliest stages of urothelial neoplasia, the determination of whether activating mutations and gene amplifications present in BCs drive cancer progression and serve as potential therapeutic targets, the identification of molecular and biological markers that can be used to distinguish "favorable" from "unfavorable" biology in non-muscle Invasive and more advanced disease that direct us to optimal therapy ("personalized medicine"), the development of novel therapeutic approaches for non-muscle Invasive BC that are alternatives to bacillus Calmette-Guerin (BCG) and/or are effective in BCG-refractory disease, and the Identification of novel agents for the treatment of metastatic BC. To achieve these goals, our SPORE has assembled clinicians and basic scientists including urologists, medical oncologists, pathologists, molecular epidemiologists, molecular and cell biologists, biostatisticians, and experts in development of new technologies and informatics. The SPORE includes 5 inter-related projects that deal with 1) early detection of BC, 2) risk assessment for BC 3) biology and therapeutic targeting of the fibroblast growth factor receptor -3, 4) therapeutic targeting of Ral GTPases, and 5.) the development of adenoviral mediated gene therapy for refractory tumors. These projects are supported by 3 Cores: (A) Administrative; (B). Biostatistics and Bioinformatics; and (C) Pathology & Data Management. All of the scientific projects are translational in nature; focus on human BC; involve clinical and basic investigators and biostatisticians; interact with the other projects; and utilize Core resources. Innovative Developmental and Career Development Projects have brought new investigators into and stimulated the SPORE that are represented in each of the major projects. Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of BC.

描述（由申请人提供）：得克萨斯大学MD安德森癌症中心孢子的总体目标是促进预防，检测和治疗这种疾病的创新转化研究，导致消除膀胱癌（BC）作为主要健康问题。我们已经投资了几个主要的翻译研究主题，其中包括：在高风险个体或监视或进行监视的早期发现非或微创标记的发展以及患有疾病患者复发的早期发现，遗传因素的鉴定，这些因素的鉴定，这些因素有助于增加或减少bc的概念和epecialitial of Meterical and epepiality and epepiality and epipeciental and epipecerial and epipeciental and epipecialiental and epipeciential core epipecientiral and epipenirential cretirential cretecrene ure ure ure ure ure ure的素养。肿瘤症，确定BCS中存在的激活突变和基因扩增是否驱动癌症的进展并作为潜在的治疗靶标，可以鉴定分子和生物学标志物，这些分子和生物学标志物可用于将“有利的”与“不利的”生物学区分开来，从而将“不利的”生物学区分为非肌肉和更先进的疾病，以实现我们的疾病，以指导我们进行最佳进化医学的发展（不可接受的进化医学）（不可接受），而不是个人化医学（”）侵入性BC是Calmette-Guerin（BCG）和/或有效的BCG-反对性疾病的替代品，并且可以鉴定出用于治疗转移性BC的新型药物。为了实现这些目标，我们的孢子已经组装了临床医生和基础科学家，包括泌尿科医生，医学肿瘤学家，病理学家，分子流行病学家，分子和细胞生物学家，生物统计学家以及新技术和信息学发展方面的专家。孢子包括5个相关的项目，可与1）早期检测到BC的早期检测，2）BC的风险评估3）生物学和成纤维细胞生长因子受体受体-3，4）RAL GTPases的治疗性靶向靶向RAL GTPases的治疗性靶向，以及5.）5。）腺病毒介导的基因治疗用于逆性抑制抑制剂的发展。这些项目得到3个核心的支持：（a）行政； （b）。生物统计学和生物信息学； （c）病理和数据管理。所有科学项目本质上都是翻译的。专注于人类卑诗省；参与临床和基本研究人员和生物统计学家；与其他项目互动；并利用核心资源。创新的发展和职业发展项目使新的研究人员进入了每个主要项目中所代表的孢子。该提案的目标和目标的实现将导致卑诗省的发病率，发病率和死亡率大大降低。